Possible surrogate marker for an effective dose-dense chemotherapy in treating ovarian cancer

Possible surrogate marker for an effective dose-dense chemotherapy in treating ovarian cancer

Objective: To dissect the correlated hematologic markers that reflect the clinical outcome or treatment response in patients receiving dose-dense chemotherapy with a combination of platinum (cisplatin or carboplatin) and paclitaxel. Materials and Methods: From 2009 to 2014, we enrolled 55 ovarian ca...

Full description

Bibliographic Details
Main Authors:	Chueh-Yi Huang, Yuh-Cheng Yang, Kung-Liahng Wang, Tze-Chien Chen, Jen-Ruei Chen, Chia-Sui Weng, Hung-Ju Chien, Chih-Long Chang
Format:	Article
Language:	English
Published:	Elsevier 2016-06-01
Series:	Taiwanese Journal of Obstetrics & Gynecology
Subjects:	dose-dense chemotherapy hematological markers ovarian cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S1028455916300390

Similar Items

Dose-dense regimen versus conventional three-weekly paclitaxel combination with carboplatin chemotherapy in first-line ovarian cancer treatment: a systematic review and meta-analysis
by: Wenjian Gong, et al.
Published: (2023-07-01)

Calculating the dose of cisplatin that is actually utilized in hyperthermic intraperitoneal chemotherapy among ovarian cancer patients
by: Wu-yun Wang, et al.
Published: (2021-01-01)

Comparison of Oncologic Outcomes of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (ddMVAC) with Gemcitabine and Cisplatin (GC) as Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis
by: Doo Yong Chung, et al.
Published: (2021-06-01)

Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy
by: Mattea Reinisch, et al.
Published: (2023-06-01)

The Safety of Chemotherapy for Ovarian Malignancy during Pregnancy
by: Naidong Xing, et al.
Published: (2022-12-01)

Maintenance Chemotherapy in Patients with Platinum-Sensitive Relapsed Epithelial Ovarian Cancer after Second-Line Chemotherapy
by: Yen-Fu Chen, et al.
Published: (2024-01-01)

Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy
by: Sylvie Giacchetti, et al.
Published: (2022-03-01)

Major Clinical Impact of Platinum-Based Chemotherapy in a Patient with a Borderline Ovarian Cancer
by: Jian Chen, et al.
Published: (2009-09-01)

Local dose-dense chemotherapy for triple-negative breast cancer via minimally invasive implantation of 3D printed devices
by: Noehyun Myung, et al.
Published: (2024-02-01)

Impressive response to oral metronomic chemotherapy in ovarian cancer
by: Dinesh Shet, et al.
Published: (2022-12-01)

Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes
by: Foteinos-Ioannis Dimitrakopoulos, et al.
Published: (2024-02-01)

Re-Evaluating Chemotherapy Dosing Strategies for Ovarian Cancer: Impact of Sarcopenia
by: Rushi Shah, et al.
Published: (2023-10-01)

Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation
by: Luca Napoleoni, et al.
Published: (2019-01-01)

Mechanistic Insights on Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
by: Olivia G. Huffman, et al.
Published: (2023-02-01)

Targeted drug conjugate systems for ovarian cancer chemotherapy
by: Omotola D. Ogundipe, et al.
Published: (2023-09-01)

Comparative Survival Outcomes of Hyperthermic Intraperitoneal Chemotherapy, Intraperitoneal Chemotherapy and Intravenous Chemotherapy for Primary Advanced Ovarian Cancer: A Network Meta-Analysis
by: Qin Tang, et al.
Published: (2023-01-01)

The Effect of Systemic Chemotherapy on Ovarian Function: A Prospective Clinical Trial
by: Filiz Çelebi, et al.
Published: (2020-07-01)

The effects and mechanism of taxanes on chemotherapy-associated ovarian damage: A review of current evidence
by: Chuqing Wu, et al.
Published: (2022-11-01)

Assessment of the Effects of Chemotherapy on Ovarian Reserve in Rats
by: Ahmet Mete Ergenoğlu, et al.
Published: (2016-04-01)

A Modified Intraperitoneal Chemotherapy Regimen for Ovarian Cancer: Technique and Treatment Outcomes
by: Ji Hyun Kim, et al.
Published: (2021-09-01)

Comparison of Long-Term Survival Rates of Primary Surgery and Surgery After Neoadjuvant Chemotherapy in Ovarian Cancer
by: Alpaslan Kaban, et al.
Published: (2019-03-01)

Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer
by: Wei-Chun Chen, et al.
Published: (2022-10-01)

Maintenance Chemotherapy for Patients with Rhabdomyosarcoma
by: Gianni Bisogno, et al.
Published: (2023-08-01)

Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer
by: Christine De Bruyn, et al.
Published: (2021-11-01)

Chemotherapy Induces Ovarian Cancer Cell Repopulation Through the Caspase 3-Mediated Arachidonic Acid Metabolic Pathway [Corrigendum]
by: Cui LZ, et al.
Published: (2022-12-01)

A combination of paclitaxel and gemcitabine in an intensive dose-dense neoadjuvant chemotherapy schedule for locally advanced breast cancer
by: I. V. Frai, et al.
Published: (2014-08-01)

Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers
by: Pei-Qi Lim, et al.
Published: (2022-09-01)

NEOADJUVANT CHEMOTHERAPY FOR EPITHELIAL OVARIAN CANCER. MODERN METHODS AND PATIENTS SELECTION CRITERIA
by: A. E. Solopova, et al.
Published: (2016-09-01)

DNA methylation characteristics associated with chemotherapy resistance in epithelial ovarian cancer
by: Changling Duan, et al.
Published: (2024-03-01)

Ovarian Cancer Stemness: Biological and Clinical Implications for Metastasis and Chemotherapy Resistance
by: Takeshi Motohara, et al.
Published: (2019-06-01)

Does Time-to-Chemotherapy after Primary Complete Macroscopic Cytoreductive Surgery Influence Prognosis for Patients with Epithelial Ovarian Cancer? A Study of the FRANCOGYN Group
by: Grégoire Rocher, et al.
Published: (2021-03-01)

Operations management of outpatient chemotherapy process: An optimization-oriented comprehensive review
by: Majed Hadid, et al.
Published: (2022-01-01)

Label-Free Quantification Mass Spectrometry Identifies Protein Markers of Chemotherapy Response in High-Grade Serous Ovarian Cancer
by: Georgia Arentz, et al.
Published: (2023-04-01)

Intensified dose-dense neoadjuvant chemotherapy using paclitaxel-gemcitabine and docetaxel-doxorubicin combinations for locally advanced breast cancer
by: I. V. Frai, et al.
Published: (2014-07-01)

Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer
by: Andrea Jewell, et al.
Published: (2018-09-01)

The Association Between Autophagy and Ovarian Cancer
by: Şayeste Demirezen, et al.
Published: (2012-08-01)

Efficacy of chemotherapy combined with surgical resection for gastric cancer with synchronous ovarian metastasis: A propensity score matching analysis
by: Jingquan Fang, et al.
Published: (2023-08-01)

Body composition as a predictor of chemotherapy-related toxicity in ovarian cancer patients: A systematic review
by: Stefania Rizzo, et al.
Published: (2022-11-01)

Chemotherapy is not necessary for early-stage serous and endometrioid ovarian cancer after undergoing comprehensive staging surgery
by: Shuqing Li, et al.
Published: (2020-08-01)

Three-step chemotherapy treatment for platinum-sensitive recurrent ovarian cancer: a review of 20 cases
by: CAI Shumo, TANG Jie, HUANG Xiao, HUANG Xiaowei, LIU Suping, KE Guihao, ZHENG Zhong, CHENG Xi, TANG Meiqin
Published: (2021-04-01)